KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.

The KDIGO 2024 chronic kidney disease guideline updates the 2012 framework with major shifts: greater use of cystatin C for GFR estimation, an individualized risk-based approach to predicting kidney failure, and broader use of SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and statins.